In patients with Retinitis pigmentosa, which of the following substances is known to have decreased levels?
Which of the following is NOT a product derived from HMG CoA?
What is the parameter that is used to assess lipid peroxidation?
X-linked adrenoleukodystrophy is a type of:
Which of the following statements about beta oxidation of fatty acids is correct?
All are true about beta oxidation of fatty acids except which of the following?
Which of the following statements about reverse cholesterol transport is false?
Which of the following is not an essential fatty acid?
Arachidonic acid oxidation involves how many cycles of beta oxidation?
What is the primary role of scavenger receptors in the development of atherosclerotic plaques?
Explanation: ***Docosahexaenoic acid (DHA)*** - **Docosahexaenoic acid (DHA)** is a crucial **omega-3 fatty acid** abundantly found in the **photoreceptor cell membranes**, particularly in the retina. - Reduced levels of DHA are frequently observed in patients with **retinitis pigmentosa**, suggesting its role in disease pathogenesis and retinal health. *Arachidonic acid* - **Arachidonic acid** is an **omega-6 fatty acid** and a precursor to many signaling molecules, but its levels are **not typically decreased** in retinitis pigmentosa. - It plays a **pro-inflammatory role** and is involved in various physiological processes, distinct from the primary metabolic defects in retinitis pigmentosa. *Linoleic acid* - **Linoleic acid** is an essential **omega-6 fatty acid** and a precursor to arachidonic acid, but its deficiencies are not characteristic of retinitis pigmentosa. - It is crucial for **skin barrier function** and overall health, but its metabolic pathways are distinct from those primarily affected in retinal degenerations. *Thromboxane* - **Thromboxane** is a **lipid mediator** primarily involved in **platelet aggregation** and vasoconstriction. - It is not directly associated with the metabolic pathways or structural integrity of the retina, and its levels are not typically altered in retinitis pigmentosa.
Explanation: ***Bile pigments*** - **Bile pigments** (like bilirubin and biliverdin) are derived from the degradation of **heme** from red blood cells and are completely unrelated to the HMG-CoA pathway. - Bile pigments are NOT products of cholesterol or isoprenoid metabolism. *Ubiquinone* - **Ubiquinone** (Coenzyme Q10) is synthesized via the **mevalonate pathway**, which begins with HMG-CoA being converted to mevalonate by **HMG-CoA reductase**. - The mevalonate pathway produces **isopentenyl pyrophosphate (IPP)**, which is used to synthesize ubiquinone, making it a downstream product of HMG-CoA. *Dolichol* - **Dolichol** is a long-chain isoprenoid alcohol essential for **N-glycosylation** of proteins in the endoplasmic reticulum. - Like ubiquinone, dolichol is synthesized from **isoprenoid units** derived from the mevalonate pathway, making it a product of HMG-CoA metabolism. *Ketone bodies* - **Ketone bodies** (acetoacetate and β-hydroxybutyrate) are directly synthesized from **HMG-CoA** in the mitochondria during fasting or low carbohydrate states. - The enzyme **HMG-CoA lyase** cleaves HMG-CoA to produce acetoacetate, which is then converted to other ketone bodies.
Explanation: ***Malondialdehyde*** - **Malondialdehyde (MDA)** is a well-established and commonly used biomarker to quantify the level of **lipid peroxidation** in biological systems. - It is a **reactive aldehyde** formed during the decomposition of polyunsaturated fatty acids, particularly through **free radical attack**. *CRP* - **CRP (C-reactive protein)** is a general **inflammatory marker** that indicates acute phase responses in the body. - While inflammation can be associated with oxidative stress, CRP itself does not directly measure **lipid peroxidation**. *hsCRP* - **hsCRP (high-sensitivity C-reactive protein)** is a more sensitive measure of **inflammation**, often used to assess cardiovascular risk. - Like standard CRP, it is an **indicator of systemic inflammation** and not a direct measure of **lipid peroxidation**. *Carboxymethyl lysine* - **Carboxymethyl lysine (CML)** is an **advanced glycation end-product (AGE)**, formed by non-enzymatic reactions between sugars and proteins or lipids. - It is a marker of **glycation and oxidative stress**, but it does not specifically measure **lipid peroxidation**.
Explanation: ***Fatty acid disorder*** - **X-linked adrenoleukodystrophy (X-ALD)** is characterized by impaired peroxisomal beta-oxidation of **very long-chain fatty acids (VLCFAs)**, leading to their accumulation. - This accumulation primarily affects the **adrenal glands** and **nervous system**, causing progressive demyelination and adrenal insufficiency. *Lysosomal storage disorder* - **Lysosomal storage disorders** involve defects in lysosomal enzymes, leading to the accumulation of specific substrates within lysosomes. - While X-ALD involves fat metabolism, the affected organelles are **peroxisomes**, not lysosomes. *Mucopolysaccharidoses* - **Mucopolysaccharidoses (MPS)** are a group of lysosomal storage disorders characterized by the defective breakdown of **glycosaminoglycans (GAGs)**, also known as mucopolysaccharides. - These disorders present with skeletal abnormalities, intellectual disability, and organomegaly, which are distinct from the primary pathology of X-ALD. *Glycogen defect disorder* - **Glycogen defect disorders** (or glycogen storage diseases) result from mutations in enzymes involved in **glycogen synthesis or breakdown**. - These conditions primarily affect carbohydrate metabolism and can lead to symptoms like hypoglycemia, muscle weakness, and hepatomegaly, distinct from the fatty acid metabolism defect in X-ALD.
Explanation: ***Correct: Fatty acid oxidation defects can lead to hypoglycemia*** - **Fatty acid oxidation** is a crucial energy source during fasting states, providing ATP and supporting **hepatic gluconeogenesis** - **Defects in fatty acid oxidation** (e.g., MCAD, LCAD, VLCAD deficiencies) impair the liver's ability to generate energy from fat breakdown - This forces continued reliance on **glucose** and impairs gluconeogenesis, leading to **hypoglycemia**, especially during fasting or increased metabolic demands - Clinically presents as **hypoketotic hypoglycemia** - a hallmark of fatty acid oxidation disorders *Incorrect: Ketone bodies are formed by complete oxidation of fatty acids during starvation* - **Ketone bodies** (acetoacetate, β-hydroxybutyrate, acetone) are indeed formed during starvation when fatty acids are mobilized - However, they result from **incomplete oxidation** of fatty acids in the liver, specifically from excess acetyl-CoA that cannot enter the TCA cycle - **Complete oxidation** would mean breakdown to CO₂ and H₂O via the TCA cycle and electron transport chain - Ketone bodies serve as alternative fuel for the brain and other tissues during prolonged fasting *Incorrect: Odd chain fatty acid oxidation provides only propionyl CoA* - **Odd-chain fatty acid oxidation** (e.g., C15, C17) yields **multiple acetyl-CoA molecules** plus **one propionyl-CoA** at the end - The word **"only"** makes this statement false - For example, a C17 fatty acid yields **7 acetyl-CoA** molecules and **1 propionyl-CoA** - Propionyl-CoA is then converted to **succinyl-CoA** (via methylmalonyl-CoA), entering the TCA cycle as a gluconeogenic substrate *Incorrect: Stearic acid on oxidation provides 120 ATPs* - **Stearic acid** (C18:0) undergoes 8 cycles of β-oxidation, yielding **9 acetyl-CoA**, **8 FADH₂**, and **8 NADH** - ATP calculation: (8 FADH₂ × 1.5) + (8 NADH × 2.5) + (9 acetyl-CoA × 10) - 2 (activation) = **12 + 20 + 90 - 2 = 120 ATP** - However, the commonly accepted value is **122 ATP** (using modern P/O ratios) or **146 ATP** (using older calculations with P/O ratios of 2 for FADH₂ and 3 for NADH) - The statement claiming exactly 120 ATP is **approximately correct but not the standard teaching value**
Explanation: ***Carnitine Acyl transferase I is stimulated by malonyl CoA*** - Malonyl CoA is a key intermediate in **fatty acid synthesis** and acts as an **inhibitor** of carnitine acyltransferase I (CAT1), not a stimulator. - This inhibition ensures that when fatty acid synthesis is active, fatty acid oxidation is suppressed, preventing a futile cycle. *Carnitine acyl transferase I is the rate limiting enzyme of fatty acid oxidation* - **Carnitine palmitoyltransferase 1 (CPT1)**, also known as carnitine acyltransferase I, is indeed the **rate-limiting step** for long-chain fatty acid entry into the mitochondrial matrix for beta-oxidation. - This enzyme controls the transport of fatty acyl-CoA into the mitochondria, which is essential for its subsequent breakdown. *Carnitine acyl transferase I is inhibited by malonyl CoA.* - **Malonyl CoA**, a precursor in fatty acid synthesis, serves as an allosteric inhibitor of **CAT1**. - This mechanism ensures that when the cell is actively synthesizing fatty acids, it simultaneously prevents their breakdown, helping to regulate overall energy metabolism. *Carnitine Acyl transferase I defect causes a decrease in acylcarnitine levels* - A defect in **CAT1** means fatty acids cannot be efficiently transported into the mitochondria to be converted into acylcarnitine for transport. - This leads to an accumulation of **free fatty acids** in the cytoplasm and a **decrease in acylcarnitine levels** in the blood and tissues, which can be used diagnostically.
Explanation: ***Lecithin Cholesterol Acyl Transferase helps in the conversion of Spheroidal HDL to Discoidal HDL*** - **Lecithin-cholesterol acyltransferase (LCAT)** catalyzes the esterification of cholesterol within HDL particles, transforming **discoidal HDL** into **spheroidal HDL**. - This process traps cholesterol esters inside the HDL core, promoting the maturation of HDL and its capacity to accept more cholesterol. *Transport of cholesterol from extrahepatic tissues to liver is true* - This statement is **true** and describes the primary function of **reverse cholesterol transport**, where excess cholesterol from peripheral cells is returned to the liver for excretion or recycling. - **High-density lipoprotein (HDL)** plays a crucial role in mediating this transport. *Cholesterol Ester Transfer Protein reduces HDL levels* - This statement is generally considered **true** because **cholesterol ester transfer protein (CETP)** facilitates the exchange of cholesterol esters from HDL to VLDL/LDL in exchange for triglycerides, which can lead to a reduction in HDL cholesterol. - This exchange process makes HDL particles smaller and more susceptible to catabolism, thus lowering **HDL levels**. *ATP Binding Cassette Transporter protein is involved in the conversion of HDL3 to HDL2* - The **ATP-binding cassette transporter A1 (ABCA1)** is primarily involved in the initial efflux of **unesterified cholesterol** and **phospholipids** from cells to lipid-poor apoA-I, forming nascent, discoidal HDL, not in the conversion of HDL3 to HDL2. - The conversion of **HDL3 to HDL2** largely depends on the accumulation of cholesterol esters within the HDL particle, which is mediated by **LCAT**, not directly by ABCA1.
Explanation: ***Palmitic acid*** - **Palmitic acid** is a **saturated fatty acid** that can be synthesized by the human body and is therefore not considered essential. - It is one of the most common fatty acids in animals and plants and is a major component of membrane lipids. *Linoleic acid* - **Linoleic acid** (an **omega-6 fatty acid**) is an essential fatty acid because the human body cannot synthesize it and it must be obtained from the diet. - It serves as a precursor for other fatty acids, including **arachidonic acid**. *Linolenic acid* - **Linolenic acid** (an **omega-3 fatty acid**) is an essential fatty acid that the human body cannot produce. - It is critical for cell membrane structure and as a precursor for other important fatty acids like **EPA** and **DHA**. *Arachidonic acid* - While important for various biological processes, **arachidonic acid** can be synthesized in the body from the essential fatty acid **linoleic acid**. - Therefore, it is considered conditionally essential, as its essentiality depends on adequate intake of its precursor.
Explanation: ***Correct Answer: 9*** - **Arachidonic acid** is a 20-carbon fatty acid (C20:4). For a fatty acid with *n* carbons, the number of beta-oxidation cycles required is **(n/2) - 1**. - Therefore, for **arachidonic acid** (n=20), the number of beta-oxidation cycles is (20/2) - 1, which equals 10 - 1 = **9 cycles**. - Each cycle removes 2 carbons as acetyl-CoA, shortening the fatty acid chain progressively. *Incorrect Option: 10* - This number represents the total number of **acetyl-CoA** molecules generated from a 20-carbon fatty acid, not the number of beta-oxidation cycles. - Each beta-oxidation cycle produces one **acetyl-CoA** and reduces the fatty acid chain by two carbons; the last cycle yields two **acetyl-CoA** molecules directly. *Incorrect Option: 20* - This value corresponds to the total number of carbons in **arachidonic acid**, not the number of beta-oxidation cycles. - The number of beta-oxidation cycles is significantly less than the total carbon count. *Incorrect Option: 8* - This number would be correct for an 18-carbon fatty acid like **stearic acid** (18/2 - 1 = 8), not for **arachidonic acid**. - The calculation explicitly depends on the exact number of carbon atoms in the fatty acid chain.
Explanation: ***Recognition and clearance of modified lipoproteins*** - Scavenger receptors, such as **SR-A** and **CD36**, primarily bind to and internalize **oxidized low-density lipoproteins (oxLDLs)** and other chemically modified lipoproteins - This process is crucial in the formation of **foam cells** within the arterial wall, a hallmark of early atherosclerotic plaque development - Unlike normal LDL receptors, scavenger receptors are not downregulated by intracellular cholesterol, leading to uncontrolled lipid accumulation *Direct pathogen killing* - While macrophages expressing scavenger receptors can participate in innate immunity, this is not their primary role in atherosclerosis - Pathogen recognition involves different receptor systems (TLRs, complement receptors) with distinct signaling pathways *Antibody production* - Antibody production is a function of **B lymphocytes**, not macrophages or their scavenger receptors - Macrophages can present antigens to helper T cells but do not produce antibodies themselves *T-cell activation* - T-cell activation requires antigen presentation via **MHC molecules** by professional antigen-presenting cells - While scavenger receptors facilitate antigen uptake, their primary role in atherosclerosis is lipid accumulation, not immune cell activation
Lipid Classification and Chemistry
Practice Questions
Fatty Acid Oxidation
Practice Questions
Ketone Body Metabolism
Practice Questions
Fatty Acid Synthesis
Practice Questions
Metabolism of Triacylglycerols
Practice Questions
Phospholipid Metabolism
Practice Questions
Cholesterol Metabolism and Biosynthesis
Practice Questions
Bile Acids and Bile Salts
Practice Questions
Lipoprotein Metabolism and Transport
Practice Questions
Dyslipidemias and Atherosclerosis
Practice Questions
Prostaglandins and Eicosanoids
Practice Questions
Fatty Liver and Lipotropic Factors
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free